The digestive system is designed to break down proteins and peptides
NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
Serena Williams weight-loss drug use sparks a moral dilemma ahead of rumoured tennis comeback The 23-time grand slam winner reentered the anti-doping testing pool, making herself eligible to return to professional tennis, but, as Jamie Braidwood outlines, the Americans use of a weight-loss drug poses a moral dilemma Bookmark CommentsGo to comments As of today (22 February), Serena Williams is eligible to return to tennis and add another chapter to her illustrious career in the sport
Previous studies suggested that both PKC activation and increased intracellular Ca 2+ levels are required for TRPM5 activation [24]
Beware: SAHPRA issues warning on illegal GLP-1 weight loss products SAHPRA warns the public about GLP-1 products sold through social media platforms
How fast is weight loss on Semaglutide GLP-1
